Details of the Drug

General Information of Drug (ID: DMTGU6K)

Drug Name

REN-1654

Synonyms

Antineurodegeneratives, Centaur; CPI-1160; CPI-1189; Parkinsons therapy, Centaur; REN-1189

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

234.29

Logarithm of the Partition Coefficient (xlogp)

2

Rotatable Bond Count (rotbonds)

3

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

2

Chemical Identifiers

Formula: C13H18N2O2
IUPAC Name: 4-acetamido-N-tert-butylbenzamide
Canonical SMILES: CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C
InChI: InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
InChIKey: DJKNRCWSXSZACF-UHFFFAOYSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
JNK signaling pathway (JNK pathway)	TTX1JEN	NOUNIPROTAC	Modulator	[2]
MAPK/ERK signaling pathway (MAPK pathway)	TT7KPH1	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00107055) Study of REN-1654 in Patients With Sciatica Pain. U.S. National Institutes of Health.
2	US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases.